<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374137</url>
  </required_header>
  <id_info>
    <org_study_id>ML30074</org_study_id>
    <nct_id>NCT03374137</nct_id>
  </id_info>
  <brief_title>Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to collect clinical data, mainly focused on safety, in the local target
      population as per the requirement of Korea Ministry of Food and Drug Safety for market
      authorization. The study population comprises patients with approved local indications
      chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical
      practice after launch.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Serious Adverse Event (AE)/Adverse Drug Reaction (ADR)</measure>
    <time_frame>from baseline until the end of the participant's observation period (up to approximately 6 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Unexpected AE/ADR</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Expected ADR</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Non-serious ADR</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with AEs of Special Interest (AESIs)</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
    <description>According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 for CLL or Cheson 2014 criteria for FL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease Rate</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
    <description>According to IWCLL 2008 for CLL or Cheson 2014 criteria for FL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Disease Rate</measure>
    <time_frame>from baseline until end of the participant's observation period (up to approximately 6 years)</time_frame>
    <description>According to IWCLL 2008 for CLL or Cheson 2014 criteria for FL</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>obinutuzumab</arm_group_label>
    <description>Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>obinutuzumab</intervention_name>
    <description>Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.</description>
    <arm_group_label>obinutuzumab</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants, who are going to receive obinutuzumab for one or more administrations
        according to medical opinions of the investigator in charge of surveillance, will be
        registered for this surveillance and treated with obinutuzumab under the approval
        conditions of the product in Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Administered obinutuzumab under the approved indications in Korea at investigator's
             discretion

          -  Previously untreated with obinutuzumab

        Exclusion Criteria:

          -  Out-of locally approved indications, dosage, and administration

          -  Pregnant women, breastfeeding women

          -  Hepatic disease

          -  Participate in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML30074 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital; Hematology-oncology</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

